Table 1.
Patient characteristics.
Figure 1.
The receiver operating characteristic curves of plasma M30 and serum ALT, AST and GGT for prediction of (a) NAFLD, and (b) NASH.
AUROC was interpreted as follows: 0.90–1.00 = excellent, 0.80–0.90 = good, 0.70–0.80 = fair, <0.70 = poor. ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT; gamma glutamyl transpeptidase; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis.
Table 2.
Accuracy of plasma M30 and serum ALT, AST and GGT for prediction of NAFLD.
Table 3.
Accuracy of plasma M30 and serum ALT, AST and GGT for prediction of NASH.
Figure 2.
Plasma M30 and serum ALT, AST and GGT levels according to fibrosis stages.
The data between and across groups were analyzed using Mann-Whitney test and Kruskal-Wallis test, respectively. The p value between groups were only shown when there was a significant difference across groups. Fibrosis was staged 0–4 (0 = no fibrosis, 1 = mild fibrosis, 2 = moderate fibrosis, 3 = severe fibrosis, 4 = cirrhosis). F, fibrosis stage; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT; gamma glutamyl transpeptidase.
Figure 3.
The receiver operating characteristic curves of plasma M30 and serum ALT, AST and GGT for prediction of (a) more severe lobular inflammation, and (b) ballooning.
AUROC was interpreted as follows: 0.90–1.00 = excellent, 0.80–0.90 = good, 0.70–0.80 = fair, <0.70 = poor. ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT; gamma glutamyl transpeptidase.